Table 5.
Ab rising ≥ 2-fold compared to day 0 | Factors | Percentagea | χ2 p-value | Odds ratio | 95% CI | p-value |
---|---|---|---|---|---|---|
Delta-infected group | ||||||
Delta IgG at day 14 | Pneumonia | 85.7% | 0.007* | 24.000 | 1.689–340.992 | 0.019* |
No pneumonia | 20.0% | |||||
Delta IgG at year 1 | Obesity | 25.0% | 0.014* | 0.063 | 0.005–0.823 | 0.035* |
Normal BMI | 84.2% | |||||
Delta IgA at day 28 | Pneumonia | 77.3% | 0.021* | 5.950 | 1.223–28.951 | 0.027* |
No pneumonia | 36.4% | |||||
Omicron IgG at day 28 | Obesity | 75.0% | 0.032* | 6.375 | 1.046–38.858 | 0.045* |
Normal BMI | 32.0% | |||||
Omicron IgA at day 14 | Hypertension | 88.9% | 0.027* | 12.000 | 1.053–136.794 | 0.045* |
No hypertension | 40.0% | |||||
Dyslipidemia | 100.0% | 0.047* | - | - | - | |
No dyslipidemia | 50.0% | |||||
Omicron-infected group | ||||||
Delta IgG at day 14 | Age ≥ 60 | 55.6% | 0.028* | 8.125 | 1.115–59.212 | 0.039* |
Age 18–59 | 13.3% | |||||
Omicron IgA at day 14 | Hypertension | 100.0% | 0.028* | - | - | - |
No hypertension | 60.0% | |||||
Omicron IgA at day 28 | Diabetes | 100.0% | 0.028* | - | - | - |
No diabetes | 58.3% |
a, Percentage of participants presented with antibody rising ≥ 2-fold in each factor category; *, statistically significant at p ≤ 0.05